The company’s PhD research focused on using lasers for precise intracellular cargo delivery. However, conversations with 100+ industry experts revealed a more critical, and technically simpler, problem in cell therapy manufacturing: removing unwanted cells. This demonstrates the value of prioritizing market needs over scientific complexity.

Instead of testing a single drug candidate in cheap models before moving to expensive ones, Gordian's parallel testing platform makes it cost-effective to use clinically relevant large animals, like horses, at the very beginning of the discovery process. This flips the traditional R&D funnel on its head.

While automation is typically associated with increasing speed, its most crucial function in complex 3D cell culture is mitigating human error and process variability. For drug discovery, where inconsistent results are a major struggle, automation provides the data consistency needed for reliable outcomes, a more valuable benefit than throughput alone.

With support from the FDA and NIH, the industry is moving to standardize organoid systems. This shift transforms them from niche research tools into reliable, quality-controlled preclinical models that can be used for personalized medicine and to generate more predictable drug discovery data.

A genetic diagnostics machine was built to speed up patient diagnosis in hospitals. However, its biggest market turned out to be pharmaceutical companies needing to prove drug efficacy. This highlights how true product-market fit can be discovered accidentally in an adjacent, more lucrative market.

Verge Labs initially focused on discovering its own drugs. The experience taught them a more valuable problem is predicting which patients will respond to a specific drug. They pivoted from trying to win the lottery to selling "a better machine that sells those lottery tickets."

Surprisingly, Portal.bio's primary engagement with large pharma companies isn't for cell therapy. Instead, pharma uses the platform to deliver normally impermeable small molecules and peptides into cells for early-stage R&D. This provides a key revenue stream while the cell therapy market is in a "trough of disillusionment."

The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.

The path to printing whole organs is being de-risked through intermediate, commercially viable applications. Companies are already generating value by printing brain tissues for R&D (e.g., for Neuralink) and simpler structures like blood vessels for surgery, proving the technology incrementally.